RAPT Therapeutics Statistics
Total Valuation
RAPT has a market cap or net worth of $153.85 million. The enterprise value is $61.07 million.
Important Dates
The next estimated earnings date is Thursday, March 6, 2025, before market open.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RAPT has 134.96 million shares outstanding. The number of shares has increased by 2.72% in one year.
| Current Share Class | 134.96M |
| Shares Outstanding | 134.96M |
| Shares Change (YoY) | +2.72% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 29.94% |
| Float | 86.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.42 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.90, with a Debt / Equity ratio of 0.05.
| Current Ratio | 9.90 |
| Quick Ratio | 9.45 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.13% and return on invested capital (ROIC) is -51.11%.
| Return on Equity (ROE) | -80.13% |
| Return on Assets (ROA) | -46.58% |
| Return on Invested Capital (ROIC) | -51.11% |
| Return on Capital Employed (ROCE) | -117.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$820,550 |
| Employee Count | 131 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.49% in the last 52 weeks. The beta is 0.01, so RAPT's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | -95.49% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 2.80 |
| Relative Strength Index (RSI) | 41.53 |
| Average Volume (20 Days) | 1,272,857 |
Short Selling Information
The latest short interest is 2.64 million, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 2.64M |
| Short Previous Month | 3.56M |
| Short % of Shares Out | 1.96% |
| Short % of Float | 3.06% |
| Short Ratio (days to cover) | 0.29 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -114.85M |
| Pretax Income | -120.43M |
| Net Income | -107.49M |
| EBITDA | -113.61M |
| EBIT | -114.85M |
| Earnings Per Share (EPS) | -$2.78 |
Full Income StatementBalance Sheet
The company has $97.91 million in cash and $5.12 million in debt, giving a net cash position of $92.79 million or $0.69 per share.
| Cash & Cash Equivalents | 97.91M |
| Total Debt | 5.12M |
| Net Cash | 92.79M |
| Net Cash Per Share | $0.69 |
| Equity (Book Value) | 95.51M |
| Book Value Per Share | 2.74 |
| Working Capital | 92.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$100.61 million and capital expenditures -$188,000, giving a free cash flow of -$100.80 million.
| Operating Cash Flow | -100.61M |
| Capital Expenditures | -188,000 |
| Free Cash Flow | -100.80M |
| FCF Per Share | -$0.75 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |